Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview
Authors
Keywords
-
Journal
Epidemiology and Psychiatric Sciences
Volume 27, Issue 4, Pages 327-335
Publisher
Cambridge University Press (CUP)
Online
2018-05-23
DOI
10.1017/s2045796018000239
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
- (2018) Philip McGuire et al. AMERICAN JOURNAL OF PSYCHIATRY
- A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia
- (2017) Ashleigh L. Osborne et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Cannabidiol: State of the art and new challenges for therapeutic applications
- (2017) Simona Pisanti et al. PHARMACOLOGY & THERAPEUTICS
- The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis
- (2017) Britta Hahn SCHIZOPHRENIA BULLETIN
- In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease
- (2017) Georgia Watt et al. Frontiers in Pharmacology
- Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents
- (2016) Pius S. Fasinu et al. PHARMACOTHERAPY
- Does cannabidiol have a role in the treatment of schizophrenia?
- (2016) Anand Gururajan et al. SCHIZOPHRENIA RESEARCH
- Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction
- (2016) María Rodríguez-Muñoz et al. Oncotarget
- Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose
- (2016) P Seeman Translational Psychiatry
- Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor
- (2015) R B Laprairie et al. BRITISH JOURNAL OF PHARMACOLOGY
- Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa
- (2014) Alexandre Schier et al. CNS & Neurological Disorders-Drug Targets
- Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary findings
- (2013) Celia J.A. Morgan et al. ADDICTIVE BEHAVIORS
- Cannabidiol for the treatment ofcannabiswithdrawal syndrome: a case report
- (2012) J. A. S. Crippa et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders
- (2012) A. C. Campos et al. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
- (2012) F M Leweke et al. Translational Psychiatry
- Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients
- (2011) Mateus M Bergamaschi et al. NEUROPSYCHOPHARMACOLOGY
- Regulation of nausea and vomiting by cannabinoids
- (2010) Linda A Parker et al. BRITISH JOURNAL OF PHARMACOLOGY
- Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report
- (2010) José Alexandre S Crippa et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)
- (2010) Jaime E. C. Hallak et al. REVISTA BRASILEIRA DE PSIQUIATRIA
- Cannabidiol was ineffective for manic episode of bipolar affective disorder
- (2008) AW Zuardi et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Cannabidiol for the treatment of psychosis in Parkinson’s disease
- (2008) AW Zuardi et al. JOURNAL OF PSYCHOPHARMACOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started